Recently, several compounds that inhibit DDX3 by binding to the DDX3 ATP binding domain or RNA binding site have been investigated for their anti-cancer properties [47], which gives hope that DDX56 may also be targetable with small molecules and used in the treatment of SqCLC. This evidence concerns the gene DDX3X and cancer.